---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-057927"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:05:58.975018+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences Q1 net loss $2.7M; cash $14.6M sufficient through 2024

## Summary
- Net loss of $2.7M ($2.46 per share) for Q1 2024, compared to net earnings of $6.2M in Q1 2023, driven by change in warrant liability.
- Cash and cash equivalents $14.6M as of March 31, 2024, up from $12.0M at December 31, 2023.
- Net cash used in operating activities was $2.8M, up from $1.6M YoY, due to clinical study expenses for GEM-AKI and GEM-SSI.
- Company believes current cash is sufficient to fund operations through 2024 based on current projections.

## SEC filing metadata
- accession: 0000950170-24-057927
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024057927/0000950170-24-057927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024057927/revb-20240510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-057927
- JSON: https://secwatch.observer/filing/0000950170-24-057927.json
- Plain text: https://secwatch.observer/filing/0000950170-24-057927.txt

## Key facts
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported the three months ended March 31, 2024 results: net income $2.7 million, EPS $2.46 basic and diluted net loss per share.
  - Period: the three months ended March 31, 2024
  - Net income: $2.7 million
  - EPS: $2.46 basic and diluted net loss per share
  - Result: reported results
  source text: Revelation’s net loss for the three months ended March 31, 2024 was $2.7 million, or $2.46 basic and diluted net loss per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017024057927/0000950170-24-057927-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.